Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Ario boosts portfolio with TRPA1 acquisition
November 2014
SHARING OPTIONS:

CAMBRIDGE, United Kingdom—Ario Pharma Ltd. has announced the acquisition of a TRPA1 antagonist research program from PharmEste, a program that includes a series of small-molecule TRPA1 antagonists, patents and related data. Ario Pharma, which has its own TRPA1 chemistry portfolio as well, plans to initiate a TRPA1 lead optimization project with a focus on orally available TRPA1 antagonist small molecules for the treatment of asthma. The TRPA1 target has demonstrated potential in inflammatory diseases and has been found to play a key role in the pathophysiology of asthma.
 
“This asset acquisition significantly strengthens Ario Pharma’s chemistry portfolio in the TRPA1 field, and we plan to select one or more development candidates within the next 18 months,” John Ford, CEO of Ario Pharma, commented in a statement. “We are overcoming solubility and pharmacokinetic issues associated with historical TRPA1 modulators developed by other companies and are excited by the level of target validation of TRPA1 in respiratory, pain and other inflammatory diseases.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.